WELBIO is an inter-university life sciences research institute based in Wallonia, Belgium. WELBIO is funded by the Walloon Region. Our mission is to support strategic fundamental research through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications in all fields of biotechnology.
Led by Benoit Vanhollebeke, WELBIO investigator at the Université libre de Bruxelles (ULB), the Laboratory of Neurovascular Signaling (ULB’s Faculty of Sciences and ULB Neuroscience Institute) provides a molecular mechanism conferring ligand specificity to Wnt signaling, an ancestral communication pathway present in all vertebrates. Their research is published in Science.
Thanks to new genomic techniques, the Animal Genomics Unit, led by Michel Georges (WELBIO investigator at Université de Liège), in collaboration with the Laboratory of Gastroenterology led by Edouard Louis (GIGA-Medical Genomics) has been able to refine its work to identify the genes responsible for Crohn’s disease. This study, published today in Nature Communications, suggests new potential targets for the development of new treatments.
A team of researchers led by Dr Pierre Close (WELBIO investigator of the GIGA Institute from ULIEGE), in collaboration with researchers from VIB, have revealed that malignant melanomas reprogram their protein synthesis machinery and become addicted to a new family of enzymes that modify transfer RNAs during acquired resistance. Strikingly, the inhibition of these molecules synergies with targeted therapies to produce a strong anti-tumoral effect. The results of this study have been published in Nature.